




RealRate

# PHARMACEUTICAL 2022

Keros Therapeutics Inc.  
Rank 125 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Keros Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Keros Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 298% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	251,440
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,846
Liabilities, Non-Current	231
Other Assets	2,476
Other Compr. Net Income	0
Other Expenses	2,011
Other Liabilities	0
Other Net Income	-360
Property and Equipment	1,335
Research and Development	55,143
Revenues	20,100
Selling, General and Administrative Expense	21,330

Output Variable	Value in 1000 USD
Assets	255,251
Liabilities	12,077
Expenses	78,484
Stockholders Equity	243,174
Net Income	-58,744
Comprehensive Net Income	-58,744
Economic Capital Ratio	22%